215 related articles for article (PubMed ID: 28534261)
21. Application of a cocktail approach to screen cytochrome P450 BM3 libraries for metabolic activity and diversity.
Reinen J; Postma G; Tump C; Bloemberg T; Engel J; Vermeulen NP; Commandeur JN; Honing M
Anal Bioanal Chem; 2016 Feb; 408(5):1425-43. PubMed ID: 26753974
[TBL] [Abstract][Full Text] [Related]
22. Enzyme kinetics for clinically relevant CYP inhibition.
Zhang ZY; Wong YN
Curr Drug Metab; 2005 Jun; 6(3):241-57. PubMed ID: 15975042
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A.
Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR
Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854
[TBL] [Abstract][Full Text] [Related]
24. Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.
Yeung CK; Fujioka Y; Hachad H; Levy RH; Isoherranen N
Clin Pharmacol Ther; 2011 Jan; 89(1):105-13. PubMed ID: 21124313
[TBL] [Abstract][Full Text] [Related]
25. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes.
Yamazaki H
Chem Res Toxicol; 2017 Jan; 30(1):53-60. PubMed ID: 27750412
[TBL] [Abstract][Full Text] [Related]
26. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
[TBL] [Abstract][Full Text] [Related]
27. Rule-Based Prediction Models of Cytochrome P450 Inhibition.
Su BH; Tu YS; Lin C; Shao CY; Lin OA; Tseng YJ
J Chem Inf Model; 2015 Jul; 55(7):1426-34. PubMed ID: 26108525
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail.
Dinger J; Meyer MR; Maurer HH
Anal Bioanal Chem; 2014 Jul; 406(18):4453-64. PubMed ID: 24830396
[TBL] [Abstract][Full Text] [Related]
29. Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method.
Yoshida K; Maeda K; Konagaya A; Kusuhara H
Drug Metab Dispos; 2018 Nov; 46(11):1805-1816. PubMed ID: 30135241
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and sort of pharmacokinetic drug-drug interactions in hospitalized psychiatric patients.
Hefner G; Wolff J; Hahn M; Hiemke C; Toto S; Roll SC; Messer T; Klimke A
J Neural Transm (Vienna); 2020 Aug; 127(8):1185-1198. PubMed ID: 32519194
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
Uchida S; Tanaka S; Namiki N
Biopharm Drug Dispos; 2014 May; 35(4):228-36. PubMed ID: 24395703
[TBL] [Abstract][Full Text] [Related]
32. Structure-based ligand design to overcome CYP inhibition in drug discovery projects.
Brändén G; Sjögren T; Schnecke V; Xue Y
Drug Discov Today; 2014 Jul; 19(7):905-11. PubMed ID: 24642031
[TBL] [Abstract][Full Text] [Related]
33. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism.
Ansede JH; Thakker DR
J Pharm Sci; 2004 Feb; 93(2):239-55. PubMed ID: 14705182
[TBL] [Abstract][Full Text] [Related]
34. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.
Kerr KP; Mate KE; Magin PJ; Marley J; Stocks NP; Disler P; Pond CD
J Clin Pharm Ther; 2014 Aug; 39(4):383-9. PubMed ID: 24702306
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation.
Murray M
Curr Drug Metab; 2000 Jul; 1(1):67-84. PubMed ID: 11467081
[TBL] [Abstract][Full Text] [Related]
36. Understanding the transport properties of metabolites: case studies and considerations for drug development.
Zamek-Gliszczynski MJ; Chu X; Polli JW; Paine MF; Galetin A
Drug Metab Dispos; 2014 Apr; 42(4):650-64. PubMed ID: 24346835
[TBL] [Abstract][Full Text] [Related]
37. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in silico Approaches to Study Cytochrome P450-Mediated Interactions.
Tan BH; Pan Y; Dong AN; Ong CE
J Pharm Pharm Sci; 2017; 20(1):319-328. PubMed ID: 29145931
[TBL] [Abstract][Full Text] [Related]
40. Metabolic interactions of magnolol with cytochrome P450 enzymes: uncompetitive inhibition of CYP1A and competitive inhibition of CYP2C.
Kim SB; Kang HE; Cho HJ; Kim YS; Chung SJ; Yoon IS; Kim DD
Drug Dev Ind Pharm; 2016; 42(2):263-9. PubMed ID: 26133083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
